<div><div></div><div><span><p><strong><span>Vaxart filed a preliminary proxy and issued an open letter urging shareholders to support its board as it advances a Phase 2b COVID-19 trial and other vaccine programs.</span></strong></p><p><strong><span>Key Highlights:</span></strong></p><ul><li><span>Filed preliminary proxy and issued shareholder letter supporting six board nominees ahead of July 16, 2026 Annual Meeting.</span></li><li><span>Phase 2b COVID-19 trial fully enrolled (~5,400 participants); 12-month sentinel safety data expected Q2 2026; primary readout anticipated early 2027.</span></li><li><span>Highlights norovirus and influenza programs as potential first-in-class and differentiation opportunities; pursuing partnerships and funding.</span></li><li><span>Reports strengthened financial position: ~$61M cash at end of Q1 2026, funded runway into Q2 2027 and $25M share purchase agreement available.</span></li><li><span>Notes actions taken to extend runway: restored BARDA funding, strategic partnership financing with Dynavax, HQ relocation, and 21% workforce reduction.</span></li></ul><p><span>Original SEC Filing: </span>Vaxart, Inc. [ VXRT ] - 8-K - May. 19, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

DVAX

VXRT

<p>Vaxart has filed a preliminary proxy and urged shareholders to support its board as it progresses with a Phase 2b COVID-19 trial. The trial is fully enrolled with 5,400 participants, and results are expected in early 2027. The company reported a strong financial position with $61M cash, ensuring funding into Q2 2027. Actions taken to extend runway include restoring BARDA funding and a strategic partnership with Dynavax.</p>

TradingView

Dynavax Tech

Vaxart

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

VG Health

Health Care Select Sector SPDR

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares US Pharma

Vaxart files preliminary proxy, urges support for board as Phase 2b COVID readout, $61M cash runway into Q2 2027